Hundreds of thousands of HIV patients could be affected by Pepfar's shift in funding policy, according to a new report.
New medicine combines ARVs into one pill, making them easier to supply.
HIV counsellors play a vital role in Lesotho's health system, but the money is running out.
Why would young, single African women not take free drugs that could potentially save them from contracting a life-threatening infection?
A global squabble over property rights could see the price of medicine soar in poor countries.
ARVs have slowed down the rate of new HIV infections and increased the life expectancy of the general population in rural KZN
A study published in the latest edition of a leading medical journal explains why the survival rate of HIV-positive women is higher than that of men.
For the first time an Aids vaccine in our lifetime is possible, but scientists need money and support to make it work.
A new report says men are able to plan their sex lives better than women and the day of the week on which the fewest people have sex is Tuesday.
Pressure's mounting on SA's Medicines Control Council to register the use of Truvada by the HIV-negative to lower chances of being infected with HIV.
South African clinicians have outlined best practice as use of the treatment to prevent infection increases, writes Mia Malan.
A large trial of the drug Truvada, hoped to be a successful HIV-preventing treatment for women, has been halted after it was found to be ineffective.
Nearly three million lives have been saved by HIV/Aids treatment, according to a new book commissioned by the United Nations.
Campaigners say breakthrough with once-a-day pill could change approaches to preventing HIV and Aids.
A leader in the search for a vaccine against HIV said on Friday that recent advances have given scientists new reason for hope.
Ngconde Balfour is disappointed that a court bid to block the release of a report on the death of an HIV-positive prisoner was dismissed on Friday.
ARV shortages are compounded by the increase in people needing treatment.
Individuals, companies and the economy are at risk if it is not dealt with effectively, argues Ian Sanne.